clinical trial · NCT06380660
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Acerand Therapeutics (Shanghai) Limited·phase2·recruiting·n = 298
Solid Tumor, AdultBRCA1 MutationBRCA2 MutationOvarian CancerBreast CancerProstate CancerACE-86225106 tablet
brief summary
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
started
Mar 22, 2024
primary completion
Dec 21, 2028
completion
Mar 21, 2029
last updated
Dec 29, 2025
detailed description
This study is a Phase I/II, open-label, multicentre study of ACE-86225106 administered orally in patients with advanced solid tumors.
official title
A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol